273 
Lilly's COVID-19 antibody cleared by FDA for post-exposure prevention
Bio Pharma Dive
SEPTEMBER 17, 2021
The expanded authorization comes amid surging demand for antibody treatments, particularly in states with lower rates of coronavirus vaccination
Antibody Related Topics 
Regeneron antibody cuts risk of COVID-19 death in UK study
Bio Pharma Dive
JUNE 16, 2021
The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Who would get Regeneron's COVID-19 antibody treatment?
Bio Pharma Dive
NOVEMBER 5, 2020
Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.
Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody
Bio Pharma Dive
JUNE 18, 2021
drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca The U.S.
Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs
Bio Pharma Dive
JULY 28, 2021
The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech
FDA clears Lilly's COVID-19 antibody cocktail for emergency use
Bio Pharma Dive
FEBRUARY 10, 2021
In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death
J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies
Bio Pharma Dive
MAY 24, 2021
Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors
COVID-19 neutralising antibody tests – an integrated approach
Pharma Phorum
JULY 6, 2021
Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. This is where antibody tests come in. Neutralising Antibodies.
A startup raises $336M to make a better antibody drug for COVID-19
Bio Pharma Dive
APRIL 19, 2021
Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests
Eli Lilly’s COVID-19 Monoclonal Antibodies Cleared to Battle Delta
XTalks
SEPTEMBER 7, 2021
After a two-month long halt, federal officials have given the go-ahead to resume nationwide distribution of Eli Lilly’s COVID-19 monoclonal antibodies bamlanivimab and etesevimab. However, studies now show the COVID-19 monoclonal antibodies can work against the variant.
US stops rollout of Lilly's first COVID-19 antibody over variant concerns
Bio Pharma Dive
MARCH 25, 2021
Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials
FDA approves Regeneron antibody drug as first Ebola virus treatment
Bio Pharma Dive
OCTOBER 14, 2020
Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19
US stocks up on COVID-19 antibody drugs amid shortage concerns
Bio Pharma Dive
SEPTEMBER 15, 2021
Deals with Regeneron and Eli Lilly will secure nearly 1.8 million additional doses of the companies' respective treatments over the next four months
F.D.A. Authorizes Another Antibody Treatment
NY Times
FEBRUARY 9, 2021
internal-essential Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.
Antibody protects against broad range of COVID-19 virus variants
Scienmag
AUGUST 21, 2021
Many of the variants circulating now are partially resistant to some of the antibody-based therapeutics that were developed based on the original virus. Medicine & Health MONOCLONAL ANTIBODIES SPIKE GLYCOPROTEIN
Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push
Bio Pharma Dive
NOVEMBER 5, 2020
Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround
In multiple myeloma, cell therapies lead but antibody drugs could follow fast
Bio Pharma Dive
DECEMBER 8, 2020
But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind Two cell therapies might soon be approved for the blood cancer.
Boehringer goes after antibody cancer drugs in latest acquisition
Bio Pharma Dive
DECEMBER 10, 2020
billion, Boehringer will take control of NBE-Therapeutics and its antibody drug conjugate technology, which has already produced one clinical-stage therapy For about $1.4
JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business
Bio Pharma Dive
JANUARY 12, 2021
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction.
Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback
Bio Pharma Dive
SEPTEMBER 14, 2020
Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020
Regeneron follows Lilly in asking for emergency approval of COVID-19 antibody drug
Bio Pharma Dive
OCTOBER 8, 2020
The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use
Boehringer takes alteplase to phase 3 for COVID, but drops antibody
Pharma Phorum
JULY 27, 2021
Boehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme later this year.
Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope
Pharma Phorum
MARCH 30, 2021
Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The post Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope appeared first on.
EMA starts review of GSK/Vir COVID-19 antibody
Pharma Phorum
APRIL 19, 2021
The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which could become the fourth drug of its type cleared for early use in the EU. . The post EMA starts review of GSK/Vir COVID-19 antibody appeared first on.
Regeneron enlists Roche to boost production of COVID-19 antibody drug
Bio Pharma Dive
AUGUST 19, 2020
Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own
As Virus Cases Surge, Biden Administration Encourages More Use of Antibody Treatments
NY Times
AUGUST 12, 2021
A top White House adviser said monoclonal antibody treatments, sometimes underused, could still be crucial in helping people with Covid-19 avoid getting very sick.
Vir breaks through with study success for COVID-19 antibody
Bio Pharma Dive
MARCH 11, 2021
A data monitoring board said a study testing Vir's drug should be stopped early because of an overwhelming benefit from treatment
AZ’s COVID jab tackles delta variant, but antibody fails clinical trial
Pharma Phorum
JUNE 15, 2021
Antibody flunks post-exposure prevention study. Eli Lilly meanwhile reported positive results with its bamlanivimab antibody in the BLAZE-2 study carried put in nursing homes, which found a 57% reduction in the risk of infection compared to placebo.
U.S. Buys 100,000 Doses of an Eli Lilly Antibody Treatment
NY Times
FEBRUARY 26, 2021
internal-essential Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Antibodies Eli Lilly and CompanyThe government will pay $210 million for the doses, which Eli Lilly will ship by the end of March.
More malaria hope as antibody protects against infection
Pharma Phorum
AUGUST 12, 2021
A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to malaria parasites for up to nine months. The post More malaria hope as antibody protects against infection appeared first on.
Provention faces delay in FDA review of diabetes prevention antibody
Pharma Phorum
APRIL 9, 2021
An advisory committee meeting to discuss the antibody is however still due to go ahead as scheduled on 27 May, according to Provention, and the FDA’s priority review is still ongoing. The post Provention faces delay in FDA review of diabetes prevention antibody appeared first on.
PROVENT trial puts AZ COVID antibody combo back on track
Pharma Phorum
AUGUST 20, 2021
AstraZeneca’s AZD7442 has shown that it can prevent COVID-19 infection when given to healthy patients – the first time this has been demonstrated by a long-acting antibody-based drug. The post PROVENT trial puts AZ COVID antibody combo back on track appeared first on.
NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial
Pharma Phorum
OCTOBER 27, 2020
According to Lilly, the NIAID took its decision on the strength of trial data which indicated that bamlanivimab – an antibody that neutralises the SARS-CoV-2 coronavirus – was unlikely to help hospitalised patients recover from advanced-stage COVID-19.
Lilly asks FDA to revoke clearance of first COVID-19 antibody drug
Bio Pharma Dive
APRIL 16, 2021
The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug
Lilly antibody drug doesn't help hospitalized COVID-19 patients in NIH study
Bio Pharma Dive
OCTOBER 27, 2020
The results could raise doubts about the ability of synthetic antibody drugs to help patients already very sick with COVID-19
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
BioTech 365
SEPTEMBER 17, 2021
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend WALTHAM, Mass.–(BUSINESS
Let's personalize your content